Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

52 results about "Opioid overdose" patented technology

An opioid overdose is toxicity due to excessive opioids. Examples of opioids include morphine, heroin, fentanyl, tramadol, and methadone. Symptoms include insufficient breathing, small pupils, and unconsciousness. Onset of symptoms depends in part on the route opioids are taken. Among those who initially survive, complications can include rhabdomyolysis, pulmonary edema, compartment syndrome, and permanent brain damage.

Pharmaceutical composition for nasal delivery

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Owner:OREXO AB

Methods and pharmaceutical compositions to treat drug overdose

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.
Owner:ENALARE THERAPEUTICS INC

Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients

A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and xylazine exposure.
Owner:MICRONEB TECH HLDG INC

Portable emergency response kits with integrated signal transmission system

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.
Owner:FFF ENTERPRISES

Design, synthesis, and biological evaluation of nitrogen-walk derivatives of nan as MU opioid receptor selective modulators

PCT designated stage expiredWO2025038406A1Organic active ingredientsNervous disorderDiseaseOpioidergic
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
Owner:VIRGINIA COMMONWEALTH UNIV

Methods and apparatuses for opioid overdose prevention

ActiveUS12718917B2OpioidergicOpioid overdose
Methods and apparatuses for opioid overdose prevention are described. The apparatus comprises a memory and at least one processor coupled to the memory. The processor is configured to receive one or more measurements related to one or more vitals of a user, and cause, based on the one or more measurements, administration of a first dose of an overdose prevention medication to the user.
Owner:JAIN UMANG +2

Pharmaceutical compositions for nasal delivery

According to the present invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist and a pharmaceutically acceptable carrier. The composition is preferably in the form of a powder produced by spray drying, which is then loaded into a disposable nasal applicator. Preferred pharmaceutically acceptable carriers in this regard include disaccharides (e.g., lactose or trehalose) and dextrins (e.g., cyclodextrin or maltodextrin), preferably spray dried in combination. The composition may further comprise an alkyl sugar, preferably a sucrose ester, such as sucrose monolaurate. The composition and applicator can be used to treat an opioid overdose in a subject.
Owner:OREXO AB

Pharmaceutical composition for nasal delivery

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Owner:OREXO AB

Wearable opioid overdose detection and alert apparatus

System involved with but not limited to an apparatus including a wearable electronic device configured to detect an opioid overdose and initiate transmission of an emergency notification to emergency services or an emergency contact. A wearable opioid detection device may detect an opioid overdose by measuring a drop in user's blood oxygen level and initiate an alarm notifying the user of decreased blood oxygen concentration. The apparatus and method of use thereof is capable of triggering an alert and communicating the wearer's location to emergency services or contacts when the user fails to cancel an alarm generated when the wearer's oxygen saturation falls below their normal saturation trend or particular fixed value.
Owner:BERMAN KYLE

Compositions and methods for the treatment of opioid overdose

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Owner:INDIVIOR INC

Wearable device for recognition and response to an overdose

A wearable device is provided for recognition and response to an overdose, such as an opioid overdose. The device includes an oximetry sensor for measuring peripheral oxygen saturation (SpO2) of a wearer of the wearable device and a motion sensor for determining whether the wearer of the wearable device is moving or motionless. The wearable device further includes an injector including a supply of an antidote and a needle for intramuscular delivery of the antidote to the wearer of the wearable device. The wearable device may also include a housing in which the oximetry sensor, the motion sensor, and the supply of the antidote is contained and in which the needle is initially contained in a retracted condition. The wearable device may further include a strap extending from the housing and sized to secure the housing on an upper arm of the wearer adjacent the shoulder of the wearer.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Naloxone buccal film product and uses thereof

The present disclosure provides a naloxone film product for treatment and prevention of opioid overdoses. Also provided is a method of making the film product. The film product comprises a naloxone composition and at least one polymer.
Owner:TAHO PHARMA +1

Remote monitoring based wearable apparatus and related method for opioid overdose detection and antidote delivery

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.
Owner:EZER ENTERPRISES LLC

Long lasting opioid reversal using hydrogen peroxide-induced release in blood

Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.
Owner:UNIVERSITY OF CINCINNATI

Opioid overdose reversal mixtures

The invention presented is a remedial opioid overdose mixture that includes a therapeutically effective dose of an opioid receptor antagonist; and, a therapeutically effective dose of an opioid receptor agonist. In one embodiment, the opioid receptor antagonist is naloxone while the opioid receptor agonist is nalbuphine. One specific naloxone derivative is NX-90 and a specific nalbuphine derivative is NB-33. The mixture can be administered intranasally, intravenously and by autoinjector. In some dose mixtures, reversal time is about three minutes.
Owner:ABERNETHY JOHN +2

Wearable Device For Opioid Overdose Detection And Antidote Delivery

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.
Owner:EZER ENTERPRISES LLC

Overdose Reviver Pressurized Spray

The Overdose Reviver Pressurized Spray, provides two different methods to administer Narcan solution intranasally, containing enough Narcan solution, and pressurized air for at least ten one second 4 mg squirts of Narcan solution with or without a 3″ long extension air tube. To aim from the base of a nostril, depress an atomizing air release valve, administering atomized, pressurized Narcan solution into the nostrils of an unconscious, opioid overdosed person. Or to remove an air release valve, insert a pressurized air canister with Narcan solution into The Overdose Reviver Automatic Inhaler, supplying the necessary pressurized air, and Narcan solution for an Automatic Inhaler to perform its automatic reviving method. Wherein a microprocessor chip detects a life-threatening low heart rate, an Automatic Inhaler will automatically, repeatedly, administer atomized, pressurized Narcan solution into the nostrils of an unconscious opioid overdosed person once every two to three minutes and alert for help.
Owner:ROBERTS KEITH ALAN

Self-Monitoring Based Wearable Apparatus And Related Method For Opioid Overdose Detection And Antidote Delivery

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.
Owner:EZER ENTERPRISES LLC

Combinations including methocinnamox

PCT designated stage expiredWO2024211481A3Nervous disorderAnhydride/acid/halide active ingredientsEndogenous OpiatesOpioidergic
Disclosed herein are compositions and methods for treating opioid use disorders, including opioid overdose with combinations including methocinnamox and at least one additional opioid modulators, for example opioid agonists, partial agonists, antagonists and allosteric modulators. The compositions and methods are also useful for treating alcohol use disorder, and other disorders associated with endogenous opioid production.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Compositions and methods for the treatment of opioid overdose

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Owner:INDIVIOR INC

Compositions and Methods for the Treatment of Opioid Overdose

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Owner:INDIVIOR INC

Intelligent dosing platform system for emergency response and pre-hospital care applications

An intelligent dosing platform system for emergency medication administration comprising intelligent injection devices with emergency protocol modules, time-based tracking systems, and AI-driven prompting systems. The system analyzes time-based administration protocols for emergency medications, monitors elapsed time since previous medication administrations, and generates next dose prompts based on protocol timing requirements and elapsed time data. A field coordination module transmits administration timing data between field emergency response teams and remote coordination systems. The system supports emergency response environments including cardiac emergencies, anaphylaxis, opioid overdose response, and military field operations. Multi-modal alert systems deliver dose prompts through audible alerts, visual electronic medical record prompts, and remote physician communications. The system prevents duplicate medication administration across emergency response teams through timing data sharing while accounting for time delays caused by patient movement and transport.
Owner:DATADOSE LLC

Naltrexamine derivatives bearing 5-member heterocyclic ring systems and opioid receptor modulators

A series of non-peptide opioid receptor modulators having the general formula: (I) is provided. In the formula: R=(II) * is a chiral carbon; M is a saturated or unsaturated, branched or unbranched, substituted or unsubstituted alkyl chain from 0-10 atoms in length; X1, X2, X3, X4, or X5 are independently, C, N, O, or S; and R is attached to M by any of X1, X2, X3, X4, or X5. The compounds are used to treat disorders related to opioid receptor functions such as opioid addiction, opioid overdose, pain and constipation caused by opioid use.
Owner:VIRGINIA COMMONWEALTH UNIV

Selective opioid receptor agonists and antagonists

Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Opioid overdose monitoring

An overdose of opioids can cause the user to stop breathing, resulting in death. A physiological monitoring system monitors respiration based on oxygen saturation readings from a fingertip pulse oximeter in communication with a smart mobile device and sends opioid monitoring information from the smart mobile device to an opioid overdose monitoring service. The opioid overdose monitoring service notifies a first set of contacts when the opioid monitoring information indicates a non-distress stats and notifies a second set of contact when the opioid monitoring information indicates an overdose event. The notification can be a phone call or text message to a specified person, emergency personnel, or first responders, and can include the location of the smart mobile device. The smart mobile device can also include the location of the nearest treatment center having emergency medication used in treating opioid overdose, such as naloxone.
Owner:MASIMO CORP

Development of broad-spectrum Anti-opioid vaccines

Provided herein are vaccine compositions comprising a hapten-conjugated to a capsid, wherein the capsid comprises wild type or native sequence, or at least one mutation. Also provided herein are vaccine compositions comprising a hapten conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and / or prevention of opioid use disorders (OUDs), including opioid addiction and opioid overdose across a broad spectrum of opioids.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV +8

Autoinjector for opioid overdose rescue

PendingAU2024402318A1Opioid overdoseNalmefene
This disclosure provides devices, delivery systems, medicaments, and methods for use to rescue a subject identified in need thereof from opioid overdose. In certain embodiments, the device is an injection device (such as, an autoinjector) for intramuscular or subcutaneous administration of a medicament comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof.
Owner:KNOA PHARMA LLC